NLRP3 and cancer: The overexpression or over-activation of gene products causes cancer cell phenotypes, so it is reasonable to expect that transfection of cells with native p53, CDK inhibitors, NLRP3 inflammasome inhibitors, and other gene products, including synthetic molecules, will suppress these phenotypes.